Drug Testing for Employers Across Multiple Locations: How a Nationwide TPA Keeps Every Site Compliant
For employers operating across multiple locations, shifts, or states, workplace drug testing often becomes inconsistent without anyone intending it to happen.
One location may use a different drug testing company than another. A second site may order a different panel, use different forms, or retain records in a separate system. Supervisors may apply reasonable-suspicion procedures differently. Human resources may receive results through several vendors with no consolidated audit trail.
The result is a patchwork program.
That structure creates operational and legal risk. If an agency, attorney, client, or internal auditor asks how a test was ordered, collected, reviewed, and reported, the employer must be able to produce a consistent record. A missing chain-of-custody document or unexplained difference between locations can weaken the defensibility of an otherwise legitimate workplace drug testing program.
A nationwide Third-Party Administrator (TPA) helps employers replace that patchwork with a controlled, repeatable process.
Why Multi-Location Testing Programs Become Difficult to Defend
Consistency is a central principle of workplace drug testing compliance. Employers should be able to show that testing decisions are based on a written policy, applied to the appropriate employees, and supported by complete documentation.
Inconsistent administration can create several problems:
Unequal treatment: Employees in similar roles may be tested under different standards depending on location or supervisor.
Discrimination and adverse-action claims: Inconsistent testing decisions can raise questions about whether a policy was applied selectively.
Incomplete records: Documentation may be divided among local vendors, paper files, email accounts, and disconnected portals.
Incorrect forms: DOT and non-DOT tests require different procedures and documentation. Mixing them can create serious compliance problems.
Delayed decisions: Results may not reach the correct Designated Employer Representative (DER) quickly enough.
Audit exposure: The employer may be unable to reconstruct the full testing event, including the collection, laboratory process, Medical Review Officer (MRO) review, and final report.
The issue is not simply whether a test was performed. The issue is whether the entire protocol can be explained and documented.
The DOT and Non-DOT Distinction Must Be Consistent Everywhere
Employers with transportation operations or other regulated positions must maintain a clear distinction between DOT and non-DOT testing.
Under 49 CFR Part 40, DOT testing procedures govern federally regulated transportation workplace drug and alcohol testing programs. DOT agency requirements may also determine which employees are covered, when random testing is required, and how employers must respond to verified results.
A multi-location program should therefore maintain separate controls for:
DOT-covered and non-DOT employees
DOT random testing pools and non-DOT testing groups
Federal Custody and Control Forms (CCFs) and non-Federal forms
DOT drug panels and employer-selected non-DOT panels
DOT removal-from-duty and return-to-duty procedures
DOT recordkeeping requirements and non-DOT personnel records
DOT rules specifically address the relationship between DOT and non-DOT testing. Employers should not use Federal forms for non-Federal collections or non-Federal forms for DOT collections. The DOT Part 40 guidance on forms and collection documentation provides the governing framework.
The separation must exist at every location, not only at the corporate office.
A Standardization Framework for Employer Drug Screening Services
Standardization does not mean ignoring local legal requirements. It means creating one controlled operating model with documented jurisdiction-specific adjustments.
A strong framework includes the following components.
1. One written policy with state-specific addenda
The core policy should define:
Who is subject to testing
Which testing events are permitted
How pre-employment, random, reasonable-suspicion, post-accident, return-to-duty, and follow-up tests are handled
Who may authorize testing
How supervisors document observations
How results are received and acted upon
How confidential information is protected
For non-DOT drug testing, the policy should also include state or local addenda where requirements differ. Those addenda should be controlled centrally rather than created independently by each location.
2. Standardized forms and chain-of-custody documentation
Every collection must be traceable from authorization through reporting. Documentation should identify the employee, reason for testing, collection date, specimen identification, collector, laboratory transfer, and final result pathway.
For DOT testing, the applicable Federal CCF and Part 40 procedures must be used. For non-DOT testing, employers should use properly designed non-Federal forms and procedures that support chain-of-custody integrity without misrepresenting the test as DOT-regulated.
3. Consistent panels and specimen types
A location should not independently change the panel, specimen type, or cutoff standard without documented authorization.
The employer should define:
The panel for each employee group
Whether urine or oral fluid is used
When an expanded panel is appropriate
Which tests are DOT-regulated
How marijuana-related results are handled in non-DOT programs
Which laboratory standards apply
For DOT testing, laboratories must meet applicable federal requirements. For non-DOT testing, a TPA can coordinate testing through appropriate accredited or certified laboratory partners based on the employer’s program and jurisdiction.
4. One MRO process
A consistent MRO process is especially important when a laboratory reports a confirmed non-negative result. The MRO reviews the result and gives the employee an opportunity to provide relevant medical information before the result is verified.
Under 49 CFR § 40.163, the MRO reports drug test results to the employer and must include required identifying and result information. DOT rules also limit the transmission of quantitative drug or validity values to the DER or C/TPA.
Using one coordinated MRO process reduces the risk that one location follows a different verification or notification procedure than another.
5. Centralized recordkeeping and retention
Employers should maintain a retrievable record of each testing event, including:
Test authorization
Employee and position classification
DOT or non-DOT designation
Collection documentation
Chain-of-custody records
Laboratory report
MRO report
Employer action
Any required follow-up or return-to-duty documentation
DOT retention requirements vary by record type. For example, 49 CFR § 40.333 identifies one-year retention for records related to negative and cancelled results and five-year retention for records related to positive results and refusals, unless a DOT agency requirement provides otherwise.
Centralized records create one audit trail instead of several disconnected files.
Multi-State Rules Require a Controlled Compliance Matrix
Non-DOT testing is not governed by one nationwide rule. State and local requirements may differ regarding:
Pre-employment drug testing
Random testing
Notice and consent
Marijuana use and medical marijuana protections
Off-duty conduct
Privacy and confidentiality
Specimen types and laboratory procedures
Adverse employment actions
Collective bargaining obligations
Employers should not assume that a policy permitted in one state can be used without modification in another. The safer approach is to establish a national baseline and identify where state-specific requirements require an exception or addendum.
In practical terms, the baseline should be designed around the strictest applicable requirement rather than the most permissive jurisdiction. That approach should still be reviewed by qualified employment counsel, particularly when the program covers multiple states, safety-sensitive positions, federal contractors, or regulated transportation employees.
DOT requirements remain separate from state legalization rules. For DOT-covered employees, the applicable federal testing and safety-sensitive employment requirements control. The DOT Part 40 regulations and applicable DOT agency rules should be reviewed alongside the employer’s non-DOT state-law matrix.
How a Nationwide TPA Coordinates the Workflow
Prime Diagnostic Testing operates as a nationwide TPA and testing coordinator. Prime is not a laboratory, medical clinic, or walk-in collection facility. Prime does not perform specimen collections itself.
Instead, Prime serves as the administrative hub connecting employers with qualified collection options, mobile or on-site collection partners, MRO services, and accredited or certified laboratory partners as appropriate to the testing program.
The coordination process can include:
Policy-to-workflow mapping: Converting the employer’s written policy into location-specific testing procedures.
Site coordination: Connecting each site with appropriate collection options, including mobile or on-site collections arranged through qualified partners when they reduce employee downtime.
DOT and non-DOT controls: Separating forms, panels, random pools, and procedures so the programs are not mixed.
Chain-of-custody management: Confirming that collection and specimen-transfer documentation follows the required protocol.
Laboratory coordination: Routing specimens through appropriate laboratory partners and tracking the testing status.
MRO coordination: Managing the review and reporting pathway for results requiring MRO action.
Consolidated reporting: Providing the employer with a centralized point of contact and organized reporting across locations.
The advantage is administrative control. Local employees may use different collection locations, but the employer does not need to manage a separate compliance process at every site.
A Practical Roadmap for Consolidating a Multi-Site Program
Employers do not need to redesign every procedure at once. A structured implementation can reduce disruption.
Step 1: Assess each location
Document the current vendor, panel, specimen type, forms, testing events, collection process, MRO, reporting method, and retention practice for each site.
Step 2: Consolidate vendor relationships
Identify which services can be coordinated through one TPA and which site-specific resources must remain in place.
Step 3: Standardize documentation
Create controlled forms, authorization procedures, chain-of-custody requirements, result-routing protocols, and retention schedules.
Step 4: Train DERs and supervisors
Those responsible for ordering tests or responding to reasonable-suspicion situations must understand the policy, documentation requirements, DOT versus non-DOT distinctions, and confidentiality rules.
Step 5: Audit and report
Review testing records by location and employee group. Confirm that procedures were followed, records are complete, and exceptions are documented and corrected.
The Clear Path Forward
Drug testing for employers across multiple locations requires more than access to collection sites. It requires policy control, process consistency, accurate documentation, and a reliable reporting structure.
Prime Diagnostic Testing helps employers coordinate that structure nationwide while keeping DOT and non-DOT requirements distinct. The objective is straightforward: one accountable administrative hub, qualified testing partners, a defensible chain of custody, and a clearer audit trail.
To review your current multi-location workplace drug testing program, call Prime Diagnostic Testing at (470) 894-4866 or contact Prime Diagnostic Testing online. You can also review the company’s DOT compliance services, employer drug testing information, and nationwide testing services.
This article provides general educational information and is not legal advice. Employers should consult qualified counsel regarding state-specific employment, privacy, marijuana, disability, collective bargaining, and workplace testing requirements.
Frequently Asked Questions
Is Prime Diagnostic Testing a laboratory or collection clinic?
No. Prime Diagnostic Testing is a nationwide TPA and testing coordinator. Prime does not operate a laboratory, medical clinic, or walk-in collection facility, and does not collect specimens directly. Prime coordinates qualified collection, MRO, and laboratory partners.
Can one employer use both DOT and non-DOT testing?
Yes, but the programs must remain clearly separated. DOT-covered employees must be tested under applicable DOT agency requirements and 49 CFR Part 40. Non-DOT testing must follow the employer’s policy and the applicable state and local requirements.
Can mobile drug testing be used for multiple locations?
Mobile or on-site collections may be available through qualified collection partners coordinated by Prime. These options can reduce employee travel and operational downtime, but the collection must still follow the applicable protocol, documentation, privacy, and chain-of-custody requirements.
Comments